3-(2-indanyl)propionic acid | 88020-86-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 3-(2-indanyl)propionic acid
• 英文别名: 3-(indan-2-yl)-propionic acid；3-Indan-2-yl-propionsaeure；β-(Hydrindyl-(2))-propionsaeure；3-(2,3-dihydro-1H-inden-2-yl)propanoic Acid
• CAS: 88020-86-4
• 化学式: C₁₂H₁₄O₂
• 分子量: 190.242
• InChiKey: JZBNSIMTJHPGGP-UHFFFAOYSA-N

物化性质

• 熔点：
  120 °C
• 沸点：
  355.2±11.0 °C(Predicted)
• 密度：
  1.137±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(2-indanyl)propionic acid 在 lithium aluminium tetrahydride 、 硫酸 作用下， 以 四氢呋喃 为溶剂， 生成 3-(indan-2-yl)-1-propanol
  参考文献：
  名称：

  血栓烷A2合成酶抑制剂。2.四氢萘和茚满衍生物的合成和活性。

  摘要：

  制备了一系列的1-咪唑基烷基取代的或5-噻唑基烷基取代的四氢萘羧酸和茚满羧酸衍生物，并测试了体外和离体对血栓烷A2（TXA2）产生的抑制活性。当口服或静脉内给药时，大多数化合物在体外均显示出有效的TXA2合成酶抑制活性，并具有长时间抑制大鼠TXA2产生的作用。咪唑类似物在体外的效价比噻唑类似物略低，但是在体外模型中咪唑类似物的活性等于或优于噻唑类似物的活性。选择6-（1-咪唑基-甲基）-5,6,7,8-四氢萘-2-羧酸盐酸盐半水合物（47a，DP-1904）进行临床研究。

  DOI：

  10.1021/jm00126a031
• 作为产物：
  描述：

  2-茚满基乙酸 在 盐酸 、 lithium aluminium tetrahydride 、 硫酸 、 氢溴酸 、 碘 、 magnesium 作用下， 以 乙醚 、 水 为溶剂， 反应 6.33h， 生成 3-(2-indanyl)propionic acid
  参考文献：
  名称：

  新的强力脯氨酰内肽酶抑制剂：茚满和四氢萘衍生物及其类似物的合成与构效关系。

  摘要：

  通过对1- [1-（4-苯基丁酰基）-L-脯氨酰基]-吡咯烷（SUAM-1221，1）或1- [1-（苄氧羰基）-L-脯氨酸]脯氨酸（Z- Pro-proalal，2）和被测试对犬脑中纯化的脯氨酰内肽酶（PEP）的体外抑制活性。在一系列缺少甲酰基或氰基的化合物中，3- [3-[（S）-2-（1,2,3,4-四氢萘基）乙酰基] -L-硫代脯氨酰基]噻唑烷（13）与1相比，效价提高了约20倍（IC50 = 2.3 nm）。具有甲酰基或氰基的化合物显示出比没有这种官能团的化合物更有效的抑制活性。在体外测试的所有化合物中，1- [1-（2-茚满基乙酰基）-L-脯氨酰基]脯氨酸（27），1- [1-[（S）-2-（1,2,3,4-四氢萘基）乙酰基] -L-脯氨酰]脯氨酸（29），1- [3-[（S）-2-（1,2,3，

  DOI：

  10.1021/jm00039a019

文献信息

• [EN] INDANE OR DIHYDROINDOLE DERIVATIVES<br/>[FR] DERIVES D'INDANE OU DE DIHYDROINDOLE
  申请人：H.LUNDBECK A/S

  公开号：WO1998028293A1

  公开（公告）日：1998-07-02

  (EN) The present invention relates to substituted indane or dihydroindole compounds of Formula (I) wherein A is an indole. These compounds have high affinity for D4 receptors.(FR) Composés d'indane ou de dihydroindole substitués, représentés par la formule (I). Dans ladite formule, A est un indole. Ces composés ont une affinité très grande vis-à-vis des récepteurs dopaminergiques D4.

  （中文）本发明涉及公式（I）中A为吲哚的取代吲哚或二氢吲哚化合物。这些化合物对D4受体具有高亲和力。
• Indane or dihydroindole derivatives
  申请人：H. Lundbeck A/S

  公开号：US20010020095A1

  公开（公告）日：2001-09-06

  The present invention relates to substituted indane or dihydroindole compounds of Formula (I) 1 wherein A is an indole. These compounds have high affinity for D 4 receptors.

  本发明涉及式(I)的取代的茚或二氢茚化合物，其中A是吲哚。这些化合物具有高亲和力的D4受体。
• CHOLINESTERASE ACTIVATOR
  申请人：ZERIA PHARMACEUTICAL CO., LTD.

  公开号：EP0754454A1

  公开（公告）日：1997-01-22

  The invention relates to a cholinesterase activator comprising, as an active ingredient, a compound represented by the following general formula (I): wherein A means a group such as a phenyl group or indanyl group, B denotes a group such as a prolyl group or thioprolyl group, and m stands for an integer of 0-5. The cholinesterase activator according to the invention has a strongly activating action on cholinesterase, in particular, a selectively activating action on peripheral cholinesterase and is also high in safety. It is hence useful as an agent for preventing and treating the side effects of central cholinesterase inhibitors, in particular, hepatopathy, and an agent for preventing and treating the side effects of various medicines manifested on the basis of a cholinesterase-inhibiting action.

  本发明涉及一种胆碱酯酶激活剂，其活性成分包括由以下通式（I）代表的化合物： 其中 A 表示苯基或茚基等基团，B 表示脯氨酰基或噻丙酰基等基团，m 代表 0-5 的整数。 本发明的胆碱酯酶激活剂对胆碱酯酶有强烈的激活作用，特别是对外周胆碱酯酶有选择性激活作用，而且安全性高。因此，它可用作预防和治疗中枢性胆碱酯酶抑制剂副作用（尤其是肝病）的药物，以及预防和治疗以胆碱酯酶抑制作用为基础的各种药物副作用的药物。
• Characterization of Potent and Selective Antagonists at Postsynaptic 5-HT1A Receptors in a Series of N4-Substituted Arylpiperazines
  作者：Jean-Louis Peglion、Herve Canton、Karin Bervoets、Valerie Audinot、Mauricette Brocco、Alain Gobert、Sylvie Le Marouille-Girardon、Mark J. Millan

  DOI：10.1021/jm00020a020

  日期：1995.9

  Benzocycloalkyl and benzocycloalkenyl moities linked, directly or via an alkyl chain, to oxygen-bearing heteroarylpiperazines were synthesized, in an attempt to obtain potent and selective antagonists at postsynaptic 5-HT1A receptors. From the numerous arylpiperazines described in the literature, 1-(2,3-dihydro-1,4-benzodioxin-5-yl)pipe (3a) was chosen as a model of an arylpiperazine in view of its selectivity for 5-HT1A receptors versus alpha(1)-, alpha(2)-, and beta-adrenergic receptors, as well as dopamine D-1 and D-2 receptors. Two other closely-related arylpiperazines, 1-(1,5-benzodioxepin-6-yl)piperazine (3b) and 1-(benzofuran-7-yl)piperazine (3c), were also examined in this study. Al compounds showed high affinity at 5-HT1A sites (8.10 less than or equal to pK(i)s less than or equal to 9.35), and the majority behaved as antagonists in vivo in blocking the hypothermia induced by the 5-HT1A agonist 8-OH-DPAT in the absence of a marked effect alone at equivalent doses. An in vivo evaluation of dopamine D-2 receptor antagonist properties revealed that the majority of compounds was devoid of activity at this site, in marked contrast to BMY 7378 which displayed virtually no selectivity for 5-HT1A versus dopamine D-2 receptors. Moreover, six compounds of the present series, 8, 10, 11, 14, 25, and, 37, showed > 10-fold selectivity in vitro for 5-HT1A versus alpha(1)-adrenergic receptors. Compound 14 displayed an optimal compromise between potency (pK(i) = 8.75), marked antagonist activity, and selectivity toward alpha(1)-adrenergic (81-fold) and dopamine D-2 (195-fold) receptors. These characteristics clearly distinguish 14 from previously-reported ligands such as the postsynaptic 5-HT1A antagonist BMY 7378 and the weak partial agonist NAN 190 which, in contrast to the compounds of this series, belong to the well-exemplified class of imido derivatives of (o-methoxyphenyl)piperazines. The availability of 14 (S 15535) should facilitate the further elucidation of the functional role and potential therapeutic significance of 5-HT1A receptors.
• Identification of a novel class of succinyl-nitrile-based Cathepsin S inhibitors
  作者：Younes Bekkali、David S. Thomson、Raj Betageri、Michel J. Emmanuel、Ming-Hong Hao、Eugene Hickey、Weimin Liu、Usha Patel、Yancey D. Ward、Erick R.R. Young、Richard Nelson、Alison Kukulka、Maryanne L. Brown、Kathy Crane、Della White、Dorothy M. Freeman、Mark E. Labadia、Jessi Wildeson、Denice M. Spero

  DOI：10.1016/j.bmcl.2007.02.046

  日期：2007.5

  The synthesis and in vitro activities of a series of suceinyl-nitrile-based inhibitors of Cathepsin S are described. Several members of this class show nanomolar inhibition of the target enzyme as well as cellular potency. The inhibitors displaying the greatest potency contain N-alkyl substituted piperidine and pyrrolidine rings spiro-fused to the alpha-carbon of the P1 residue. (C) 2007 Elsevier Ltd. All rights reserved.